WallStSmart

Hudbay Minerals Inc. (HBM)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hudbay Minerals Inc. generates 4365% more annual revenue ($2.47B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 27.5%. HBM trades at a lower P/E of 14.0x. HBM earns a higher WallStSmart Score of 70/100 (B-).

HBM

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 8.5Value: 5.7Quality: 6.0
Piotroski: 4/9Altman Z: 1.63

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.5Value: 5.3Quality: 7.5
Piotroski: 5/9Altman Z: 1.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HBM5 strengths · Avg: 8.6/10
Operating MarginProfitability
32.6%10/10

Strong operational efficiency at 32.6%

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
14.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
17.7%8/10

17.7% revenue growth

VMET6 strengths · Avg: 9.5/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

HBM2 concerns · Avg: 4.0/10
PEG RatioValuation
2.094/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.634/10

Distress zone — elevated risk

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
28.7x4/10

Moderate valuation

Market CapQuality
$933.87M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HBM

The strongest argument for HBM centers on Operating Margin, Profit Margin, P/E Ratio. Profitability is solid with margins at 27.5% and operating margin at 32.6%. Revenue growth of 17.7% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : HBM

The primary concerns for HBM are PEG Ratio, Altman Z-Score.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 594.0% — sustainability is the question.

HBM generates stronger free cash flow (70M), providing more financial flexibility.

Monitor COPPER industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HBM scores higher overall (70/100 vs 60/100), backed by strong 27.5% margins and 17.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hudbay Minerals Inc.

BASIC MATERIALS · COPPER · USA

Hudbay Minerals Inc., a diversified mining company, focuses on the discovery, production and marketing of base and precious metals in North and South America. The company is headquartered in Toronto, Canada.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?